Palliative Care and Transplant

Early palliative care integration has increased in oncologic settings but remains less common − and often misunderstood − in hematologic malignancies, especially for patients undergoing hematopoietic cell transplant. When Dame Cicely Saunders founded the first...

Online Exclusives

Analysis of COVID-19 Clinical Trials Reveals Disorganization and Wasted Resources

An analysis cosponsored by STAT and AppliedXL, a Newlab Venture Studio company, found that clinical trials for treatments and preventative strategies for COVID-19 were...

New FDA Platform Criticized for Lack of Demographic Information

The new FDA platform Project Patient Voice, is a public database of patient-reported outcomes for clinical trials of cancer treatments intended to give patients...

News

From the Blood Journals

WIB_icon

Lenzilumab Demonstrates Clinical Benefit in Patients With Chronic Myelomonocytic Leukemia

A phase I study found that lenzilumab, an engineered human IgG1K monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), was associated with a clinical...
WIB_icon

Radiation Alone Improves Outcomes in Early-Stage NLPHL Without High-Risk Features

Radiotherapy alone was associated with excellent progression-free survival (PFS) and low rates of late toxicity in patients with stages IA to IIA nodular lymphocyte-predominant...

Multimedia

Constantine Tam: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia

Treatment with zanubrutinib resulted in a higher combined complete response and very good partial response rate than therapy with ibrutinib in patients with Waldenström...

John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with pembrolizumab prolonged progression-free survival more than brentuximab vedotin, including in patients ineligible for transplant. Dr. Kuruvilla discusses results from the phase III...

Meletios Dimopoulos: Weekly SVd Improved PFS in Relapsed/Refractory Myeloma

Once weekly combination treatment with selinexor, bortezomib, and dexamethasone led to an approximately 4-month improvement in progression-free survival compared with bortezomib plus dexamethasone. Meletios...

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed Myeloma

Initial treatment with carfilzomib, lenalidomide, and dexamethasone was not associated with greater improvements in progression-free survival compared with bortezomib, lenalidomide, and dexamethasone. Shaji Kumar,...

On Location

On location

ENDURANCE: Comparing KRd With VRd in Newly Diagnosed Myeloma

Initial treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) was not associated with longer progression-free survival...
On location

DVT Increases Health-Care Burden and Mortality in Patients with Cancer

Patients with cancer and deep vein thrombosis (DVT) experience higher rates of hospitalization and mortality,...
On location

DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma

Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and...
On location

BOSTON: Weekly Combination Therapy Including Selinexor Improved PFS in Relapsed/Refractory Myeloma

Once weekly combination treatment with selinexor, bortezomib, and dexamethasone (SVd) led to an approximately 4-month...
On location

ASPEN: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia

Treatment with the selective Bruton tyrosine kinase (BTK) inhibitor zanubrutinib resulted in a higher combined...
On location

KEYNOTE-204: Pembrolizumab Superior to Brentuximab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with anti-PD-1 antibody pembrolizumab prolonged progression-free survival (PFS) more than brentuximab vedotin (BV) in...

Latest Headlines

Advertisement

ASH Directions

ASH Directions

ASH Selects Next Congressional Fellow, and more

ASH Selects Next Congressional Fellow Jerome Seid, MD, has been selected by the American Society of Hematology (ASH) to be the next ASH Congressional Fellow....
ASH Directions

ASH Hosts Webinar on Treating COVID-19 With Convalescent Plasma, and more

On May 12, the American Society of Hematology (ASH) hosted a webinar on the use of convalescent plasma (i.e., plasma from patients who have...

Sign up for our
eNewsletter!

The Society Pages

Remembering Earl Davie, Clive Kearon, and more

Remembering Earl Davie, PhD (1927 – 2020) Biochemist Earl Warren Davie, PhD, died on June 6, 2020, at the age of 92.Dr. Davie was Professor...
The Society Pages

Marc J. Kahn Named Dean of UNLV School of Medicine, ASH Members Are Finalists...

Marc J. Kahn Named Dean of UNLV School of Medicine Marc J. Kahn, MD, has been appointed the dean of the School of Medicine at...
The Society Pages

CPRIT Awards $19.6 Million to MD Anderson, Sidney Kimmel Establishes Philadelphia T-cell Lymphoma/Leukemia Initiative,...

Sidney Kimmel Cancer Center at Jefferson Establishes Philadelphia T-cell Lymphoma/Leukemia Initiative The Sidney Kimmel Cancer Center – Jefferson Health (SKCC at Jefferson) will use a...

Palliative Care and Transplant

Early palliative care integration has increased in oncologic settings but remains less common − and often misunderstood − in hematologic malignancies, especially for patients...

Coagulation Dysregulation

Thrombosis is a major contributor to death in patients with severe coronavirus infection. As new data emerge, experts discuss approaches to prevention and treatment. In...

Medicine and Machines

As artificial intelligence applications broaden, experts advise physicians to approach them as tools – not threats. Tools have been invented to aid physicians and improve...